Previously, things like excrement and secretions were manually inspected, which was both dirty and tiring. To address this industry pain point, the company is committed to applying 'artificial intelligence + machine vision technology + big data' to the morphological testing of clinical specimens in medical and health institutions, driving the industry's development from manual to automated microscopy. This was stated by Aiwei Technology Chairman Ding Jianwen in an interview with the Securities Daily reporter.
As a recipient of the national "Ten Thousand Talents Program," Ding Jianwen has a deep affection for the automated microscopy industry and its products. Under his leadership, Aiwei Technology has driven product incubation through technological innovation and has gained recognition from over 6,000 hospitals in China.
How will Aiwei Technology further expand into primary medical care and consumer product markets in the future, and uncover more business opportunities in in-vitro diagnostics? Recently, the Securities Daily reporter, along with numerous institutional investors, visited Aiwei Technology to explore the future prospects of the company's automated microscopy technology.

Cutting-edge technology applied to clinical medicine
Entering the Aiwei Technology product display area, a production line approximately four meters long and over one meter wide, composed of multiple white instrument modules, caught the reporter's eye. Urine test tubes were quickly transported on the specimen tube conveyor module to various testing positions for testing, and the adjacent computer screen displayed comprehensive test results with text and images. The specimen transportation and testing were seamless and incredibly fast.
Aiwei Technology's Vice General Manager, Lin Changqing, introduced to the Securities Daily reporter: "This is the company's newly launched AVE-7200 fully automated urine analysis modular production line, which can detect and analyze 14 dry chemistry items in urine, such as occult blood and white blood cells. Simultaneously, it uses artificial intelligence machine vision technology and an automated morphological microscopy method to automatically identify and count formed elements in urine."
It is understood that this product can complete fully automated testing of urine physics and dry chemistry, as well as fully automated microscopy of formed elements in urine, generating a comprehensive report containing multiple analysis results, including urine physics, dry chemistry, and morphology, providing comprehensive diagnostic indicators for clinical use. It has begun application in the testing departments of extra-large tertiary hospitals.
It is understood that the above-mentioned product is just one of Aiwei Technology's flagship products. To date, Aiwei Technology's medical testing instruments have accumulated over 15,000 units installed in China, and have been installed in over 6,000 hospitals nationwide. Among them, the company's urine testing, stool testing, and reproductive tract secretion testing products are in a leading market position.
Lin Changqing stated: "Many well-known tertiary hospitals in China, such as the China-Japan Friendship Hospital, Xiangya Hospital of Central South University, and the First Affiliated Hospital of China Medical University, have installed our products. The company has accumulated over 4,200 units installed in tertiary hospitals across China."
While achieving market leadership in instruments, Aiwei Technology actively develops supporting reagents and consumables, forming a virtuous cycle of instrument promotion driving sales of supporting reagents and consumables, laying a solid foundation for the company's continued growth.
In 2023, the company's revenue exceeded 200 million yuan, a year-on-year increase of 1.79%; net profit attributable to the parent company reached 21.53 million yuan, a year-on-year increase of 19.81%. In the first quarter of this year, the company's performance continued its growth trend, achieving revenue of 46.8138 million yuan, a year-on-year increase of 14.46%; net profit attributable to the parent company was 5.07 million yuan, a year-on-year increase of 136.42%.

Expanding into primary medical care and consumer markets
With a leading market share in the hospital market, Aiwei Technology is actively expanding into consumer products and primary medical care markets to create new profit growth points.
"This Helicobacter pylori test strip home self-test card is one of the products aimed at the consumer market." Lin Changqing introduced the company's product to the reporter, "Just open the diluent tube cap, use the sampling spoon attached to the cap to sample the stool, then tighten the cap and shake the liquid repeatedly, then drop it into the sample well of the test card, and the result can be read within 10 to 15 minutes."
It is understood that, using such rapid detection products as an entry point, Aiwei Technology will next focus on developing the consumer medical market. The company has developed dozens of lightweight POCT/iPOCT products for the consumer medical market focusing on chronic disease management, health monitoring, and home self-testing, covering women's health, scientific pregnancy, childhood diarrhea, early tumor screening, gastrointestinal diseases, urinary system diseases, diabetes, and health checkups. These products are launched on major e-commerce platforms, targeting individual consumers.
In addition, the primary medical care market will also be another key area for Aiwei Technology. The company has developed small, multi-functional instruments for primary medical and health institutions, considering their small scale, low specimen volume, and low automation requirements, to meet the clinical testing needs of primary medical and health institutions.

Attracting institutions to conduct research
Based on the company's high-tech content and multi-segment strategic deployment, Aiwei Technology's research activity attracted over 20 representatives from well-known institutions, including Hunan Qingyan Venture Capital Management Co., Ltd. (hereinafter referred to as "Qingyan Venture Capital"), Hunan Huazhou Investment Private Equity Fund (hereinafter referred to as "Huazhou Investment"), Hunan Fuchuan Private Equity Investment Fund, and Fangzheng Hesheng Investment.
In addition, Tianjian Accounting Firm's Hunan branch, as the organizer, also participated in the exchange. This is the first time a Hunan listed company has invited an audit firm to participate in an "in-person" investor exchange.
Industry insiders said that encouraging audit firms to directly face market investors is beneficial for investors to understand listed companies from multiple perspectives, further strengthens the responsibility of audit firms as "gatekeepers," and promotes the "two-way rush" between Hunan institutions and local enterprises, helping the company attract more "patient capital."
After conducting in-depth research on Aiwei Technology, Chen Zhaoqian, a representative of Qingyan Venture Capital, said in an interview with the Securities Daily reporter: "The R&D cycle for medical devices is long, and the barriers to entry are high. As a pioneer and leader in automated microscopy technology in China, the company has a first-mover advantage. The launch of the company's primary and consumer product lines is expected to become an important business growth point for the company in the future."
"Being able to become an instrument and reagent supplier for numerous tertiary hospitals shows the reputation of the company's products." While giving affirmation, Li Liping, a representative of Huazhou Investment, also made some suggestions for Aiwei Technology: "In the future, we hope the company will further strengthen its marketing efforts to increase its market share, and we look forward to the explosive growth of the company's primary and consumer product lines."